Medtronic (NYSE: MDT) Reports Strong Q1 2026 Earnings and Robust Financial Health

Font: Financial Modeling Prep  • Jun 03, 2026

• Medtronic exceeded analyst expectations for both quarterly earnings and revenue, showcasing strong operational performance.
• Strategic initiatives undertaken by the medical technology giant have successfully driven improved profit and sales figures.
• The company demonstrates solid financial health, characterized by a competitive price-to-earnings (P/E) ratio, a healthy debt-to-equity ratio, and strong liquidity with its current ratio.

Medtronic (NYSE: MDT) is a global medical technology company. It develops and manufactures a wide range of devices and therapies. These products help treat chronic diseases, including heart conditions and diabetes, positioning Medtronic as a key player in the healthcare sector.

On June 3, 2026, Medtronic reported quarterly earnings of $1.55 per share, which narrowly beat the analyst consensus estimate of $1.54. As highlighted by Zacks, this figure is a decrease from the $1.62 per share reported in the same quarter of the previous year.

The company also announced strong quarterly revenue of $9.81 billion, surpassing the consensus estimate of $9.61 billion. As noted by The Wall Street Journal, the higher profit and sales are attributed to strategic steps taken by Medtronic to improve its business performance.

From a valuation standpoint, Medtronic has a price-to-earnings (P/E) ratio of approximately 20.49. This metric shows what investors are willing to pay for each dollar of earnings. The company also has a price-to-sales ratio of 2.67, comparing its stock price to its revenues.

Examining its financial health, Medtronic maintains a debt-to-equity ratio of 0.57. This ratio measures a company's debt relative to the value owned by shareholders. Its liquidity appears strong with a current ratio of 2.54, indicating a solid ability to meet short-term financial obligations.